An immobilized form of Candida antarctica lipase B (CAL-B) has been developed with enhanced stability and activity compared to commercially available preparations. The immobilized CAL-B is more active, and 15 times more stable than the previously used preparation. This permits a continuous dynamic kinetic resolution process that is significantly less expensive than the original batch process, and with a 3-fold reduction in the process E -factor.
No takes yet. Share an insight, caveat, or question.
Truppo et al. (2011) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: